Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $3.53 Million - $5.26 Million
-115,000 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $1.61 Million - $2.29 Million
40,000 Added 53.33%
115,000 $5.1 Million
Q2 2021

Aug 13, 2021

BUY
$54.88 - $79.29 $4.12 Million - $5.95 Million
75,000 New
75,000 $4.26 Million
Q2 2020

Jul 16, 2020

SELL
$25.95 - $43.15 $1.3 Million - $2.16 Million
-50,000 Closed
0 $0
Q4 2019

Jan 17, 2020

BUY
$60.18 - $154.77 $1.81 Million - $4.64 Million
30,000 Added 150.0%
50,000 $3.61 Million
Q3 2019

Oct 16, 2019

SELL
$140.29 - $189.96 $229,935 - $311,344
-1,639 Reduced 7.57%
20,000 $2.81 Million
Q2 2019

Jul 22, 2019

SELL
$157.85 - $183.09 $4.74 Million - $5.49 Million
-30,000 Reduced 58.1%
21,639 $3.96 Million
Q1 2019

Apr 11, 2019

SELL
$89.33 - $163.65 $7.66 Million - $14 Million
-85,700 Reduced 62.4%
51,639 $8.21 Million
Q4 2018

Feb 05, 2019

BUY
$81.94 - $139.71 $1.03 Million - $1.76 Million
12,600 Added 10.1%
137,339 $13.2 Million
Q3 2018

Oct 03, 2018

SELL
$138.11 - $169.04 $682,263 - $835,057
-4,940 Reduced 3.81%
124,739 $17.6 Million
Q2 2018

Jul 20, 2018

BUY
$140.36 - $175.76 $4.87 Million - $6.1 Million
34,679 Added 36.5%
129,679 $20.3 Million
Q1 2018

Apr 11, 2018

SELL
$152.15 - $192.33 $1.51 Million - $1.91 Million
-9,930 Reduced 9.46%
95,000 $15.3 Million
Q4 2017

Jan 19, 2018

BUY
$60.72 - $167.34 $3.34 Million - $9.19 Million
54,930 Added 109.86%
104,930 $17.3 Million
Q3 2017

Oct 13, 2017

BUY
$61.4 - $88.52 $3.07 Million - $4.43 Million
50,000
50,000 $3.12 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $643M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.